OneStart Top 10 Finalists
-
Upload
johndaley89 -
Category
Education
-
view
2.276 -
download
1
Transcript of OneStart Top 10 Finalists
anywhere
Providing rapid, robust and reliable diagnosis and disease monitoring and analysis at the point of care: By the patient, for the patient.
The team
• Dr Nick Brooks
• Dr Ali Salehi-‐Reyhani
• Dr Duncan Casey
• David Edwards
Project Management
Scien0fic / Applica0on Development
Itera0ve Product Development
Commercial Development
IP, Legal & nego0a0on advice
Dr Nick Brooks
Dr Ali Salehi-‐Reyhani
Dr Duncan Casey
Imperial Innova>ons
David Edwards
The team Dr Nick Brooks
• Research lecturer at the Institute of Chemical Biology (ICB) at Imperial College.
• Successful background in high pressure instrument design, leading projects at international research centres.
Dr Ali Salehi-Reyhani • Post-doctoral researcher at the ICB with a PhD in microfluidic
engineering. • Specialises in development of lab-on-a-chip devices.
Dr Duncan Casey • Post doctoral-researcher at the ICB with a PhD in HPLC of
biological membranes. • Multidisciplinary researcher building optical tools for cell
biology. David Edwards
• Chemistry trained, with significant commercial experience developing product portfolios and routes to market.
• Leads financial and market modelling efforts for the project.
OneStart funded development
• The OneStart funding will be used to develop a fully func>onal modular β-‐prototype based on exis>ng concept designs over a 9 month period.
• The £100,000 will allow us to employ an engineering based researcher for 9 months, will fund specialist manufacturing consultancy costs and allow us to have 3 design itera>ons manufactured by external workshops.
• This prototype will form a plaNorm for applica>on specific op>misa>on in later stages of the project and will facilitate follow-‐on funding applica>ons.
���������
����� ����� ��� �'�� '(�&()% �,%!$�(�#���##$*�(�*��#�+
(���#$!$�-�($�"$#�($&�%�(��#('�+�(� ���&(���'��'�'� ����#���!�#���!
����'�$#'��#������#��'��#�����#(�*�!)��($����!(���&��%&$*���&'�
����&�����&$)%�$� ��%��&�$�����#!��!���$!" �&$"�(��
�#�*�&'�(-�$����"�&�����+�(���,%�&��#����#��!��(&$#��
�#��#��&�#�� #�#$���$(���#$!$�-���$"%)(�(�$#�!���$!$�-��#�
�)'�#�''���*�!$%"�#(�
�)&��$"%!�"�#(�&-���� �&$)#�'��$&"��#��,��!!�#(
�$)#��(�$#��$&�(���')���''�$��(���%&$%$'����#(�&%&�'��
��������������������#���
� ���#��� �!������� ���&"��$��#$"��'
� �!��$�"���!������������ "��&$�!��(&$#��'��
#�#$(���#$!$�-��$&����!(���&�
� �$����$ �� �(�(�'(���!���#�(��'��#��#�(+$& ���$!$�-
� �! �!�� ��������� ��$(���#$!$�-��$#')!(�#�-�
�#(&�%&�#�)&��!�"�#���"�#(��#� ��$#�#$(���
� ���������' $�'���!���� ��$�#�$&"�(��'
����#�!# �!�'�
� �)&�*�'�$#��'�($�)'��(�� �#��(�&( %&�.� ($�(&�#'�$&"�$)&
%�(�#(���'�#'�#��%!�(�$&"��#($�� �!�������������#
��%�������#������ "�##���
� ���'�+�!! �#��!��)'�($�'�� ���� ������� ($���&&-�(��
%&$�)�(�(�&$)���(���&��)!�($&-��%%&$*�!�%&$��''
!�������������#
��%�������������#$!�"
� ��&�!!�! '�#'�#��$��'�*�&�! ��
��$"�& �&'����
� ��#��()&�'����!��(&$#��'
� �#(��&�(���+�(����"$��!��%�$#�
*����������!�
� ��"%!���%%��$&���*����$)(%)(
High precision, wireless, automated home based foetal monitoring for pregnant mothers to monitor their babies themselves,
anytime and anywhere.
www.foetoh.com
Team
Dr. Michelle Fernandes • Co-founder and Leader Clinical Core (MBBS, DPhil. University of Oxford) • Expertise: Foetal neurodevelopment, foetal medicine, and antenatal monitoring • 1+ years of experience in clinical medicine, 6+ years of experience in research medicine • Current affiliation: FoetoH, the Nuffield Dept. of Obstetrics & Gynaecology, JR Hospital, Oxford
Dr. Ricardo Pachon • Co-founder and Leader Technology Core (MSc, DPhil. University of Oxford) • Expertise: pattern recognition automation, numerical mathematics • Co-author of Chebfun, a scientific computing software. • Current affiliation: FoetoH, CS Group AG
Medical Advisory Committee Dr. J. Hemelaar, the John Radcliffe Hospital, Oxford Dr. G. Menezes, Snehalaya Hospital, Solur, India
Prototype Advisory Committee Ning Zhang, , University of Oxford, UK Abhishek Appaji, BMSCE, Bangalore, India Luis Aranzeta, CTIN, Mexico Jomichael Porter, Stanford University, USA Riverlite Ltd., UK
Business Advisory Committee Allan Rodriguez, Dell Inc., USA Will Chadwick, TATA Interactive Systems, UK Simon Bennett, Simon Bennett Associates, UK Marks & Clerk LLP, UK
2013 2014 2015 2016 2017 2018
Key Milestone
Prototype Product
Dev. Pilot sales
UK UK
launch* European launch*
US launch*
No. Units 1 20 90 200 Revenue 250 5,000 22,500 50,000
Expenses 100 270 880 3,700 10,000 16,000
Profit (100) (270) (630) 1,300 12,500 34,000
Cashflow (100) (370) (1,000) 300 12,800 46,800
The Case to Onestart
£100,000 Completely facilitate Phase II: 1. The development of the beta prototype 2. Preliminary laboratory & clinical testing of the beta 3. CE marking 4. The full time involvement of the team in a dedicated FoetoH office 5. Initial conversations with MNOs &larger medical device manufacturers 6. Accelerate pilot sales to Q3 2014
Figures in ‘000s, Currency GBP, *Associated with commercialization partners. Assumes retailing at £250 per unit; cost per unit of £35.
HackeR Biologics, Cambridge, UK [email protected]
Hackett Biologics has developed a proprietary technology that stabilises stem cells at room temperature, removing the consequences
associated with freezing
The Team
• Previously assistant professor of regenera>ve medicine at Linkӧping University in Sweden, scien>st/strategy lead at Pfizer Neusen>s, Director of Business Development for Bodymetrics.
• President and CSO of HackeR Biologics since 2009 and currently the strategic & commercial partnerships execu>ve at the Royal Society of Chemistry
• PhD and postdoctoral research in regenera>ve medicine and >ssue engineering
Dr. Joanne M. HackeR, Founder and CSO
• Experienced stem cell biologist at the University of Cambridge, Linkӧping University and University of ORawa
• Herchel Smith Research Associate – University of Cambridge • Consultant at HackeR Biologics since 2009 • PhD and postdoctoral research in neural stem cell differen>a>on and prolifera>on
Dr. Ryan B. MacDonald, Project Manager and Scien>fic Advisor
The £100,000 investment…
Will be used to: – protect intellectual property – engage advisors, commercial consultants and collaborators
– undertake further stability and characteriza>on studies – perform feasibility studies on addi>onal cell lines
• generate revenue which can be reinvested to secure licensing deals with major companies
– provide seed funding for future grant applica>ons (e.g. TSB)
Natalie Cureton 1st year PhD student in
Nanotechnology sponsored by the BBSRC DTP
BSc Pharmaceu>cal Science (2012)
Anna King 2nd year PhD student in
Nanotechnology sponsored by the NowNano DTC
MPhys Physics (2011) Innova>on and
Commercialisa>on of research (2012)
Dr. Lynda Harris BBSRC David Phillips Research Fellow (2010-‐2015) PhD (2003)
BSc Pathobiology (1999)
The £100,000 prize will:
§ Give us the financial support required to complete full toxicology and safety studies
§ Enable us to purchase instruments to assist in the manufacture of larger quan00es of LipoPep
§ Allow us to explore delivery of different therapeu0cs
§ Provide us with the founda0on required to take LipoPep through Phase I and Phase II clinical trails
MPDx TECHNOLOGIES
THE MISSING PIECE – Enabling True Point of Care Diagnos4cs
MPDx INTERDISCIPLINARY TEAM
Maa Wilkinson MBA Business Development Experienced technical sales and marke>ng industry professional
Devaki Bhaaa PhD Scien0fic Director 10+ yrs diagnos>cs start-‐up experience Mul>-‐disciplinary exper>se (business & technical)
Andy Dixon MSc Chief Engineer Lab automa>on specialist & inventor on core patents
Liz Nyeko MBA Finance Officer Background in investment banking focused on healthcare
Prof Judith Hall MD OBE Clinical Lead, Cardiff Hospital Cri>cal care consultant with 30+ yrs exper>se in diagnosis and early interven>on in sepsis; Able to influence NHS technology adop>on strategy
Mark Phillips SVP GSK Diagnos0cs Senior execu>ve with 25+ yrs diagnos>cs & pharma experience Early-‐stage biotech business mentor
Prof Chris Lowe OBE Director of Biotechnology, University of Cambridge 35+ yrs experience in healthcare technology commercialisa>on ‘Most entrepreneurial scien>st of the UK’
Core Team
Advisory Board
USE OF ONESTART £100K
• Genera0on of comprehensive data pack comprising key applica0on-‐
specific test results
• Significant advances in next-‐genera0on prototype development
• Recruitment of key hires (scien0st, engineer) to enable above
Importantly, OneStart financing will enable MPDx to leverage significant government grants, crea>ng added value and posi>oning the company as an aRrac>ve investment opportunity.
Picoto offers a comprehensive, portable newborn monitoring solution to bring a new global standard of care through unique sensors and intelligent data fusion algorithms.
Picoto is the brainchild of several University of Oxford researchers who specialize in data analytics, biotechnology innovation, and clinical medicine:
The Operational
team The
Technology team
The Medical
team
We are also supported by a stellar group of advisors from international organizations vested in the development of better clinical care and practice
Oliver Bent Mohammed Shahid Jon Daly Dr. Violeta Monasterio
Dr. Alexander Finlayson Jayson Marwaha
Sana Fathima
Elnaz Gederi Maxim Osipov
Starting with OneStart.
The One Start Prize money will be used to finish the final prototype and validation studies. The 100k
OneStart Prize
Final Prototype
Regulatory Approval
Validation Studies
Towards 1st Round
Seed Funding
Next genera+on purifica+on for today’s and tomorrow’s biotherapeu+cs – reducing
manufacturing costs by 25%
Oliver Hardick, EngD Founder & CEO Current: Postdoctoral Fellow at UCL in Biochemical Engineering, a recognised world expert in nanofibre
purifica>on and original inventor of FibroSelect
Experience: Director property company (4 years); Research Engineer – STFC (4 years); Consultant (intern)
Academics: EngD (UCL); BEng 1:1 (UCL); -‐ Sir Derek Roberts Scholarship (2005), Jacobs Engineering Award (2008), Finalist Material Science Sapphire Prize (2011), BioProducts Laboratory Prize (2012)
Iwan Roberts, MEng, MRes Co-Founder & COO Current: Final year doctoral student in Biochemical Engineering (EngD)
Experience: IMS Consul>ng Group (internship); UK Parliament (adviser), experience in running technological feasibility studies for companies, worked with Oliver on various projects over the last 7 years
Academics: MRes Dis>nc>on (UCL), MEng 1:1 (Deans list, UCL), completed entrepreneurial MBA modules at London Business School
Tom Haywood, CFA Co-founder & CFO Current: Part-‐>me policy adviser for the CFA Society of the UK
Experience: Investment Banking (Deutsche Bank 3 yrs); Accoun>ng (DeloiRe 1 yr)
Academics: CFA Charterholder; MSc in Biodiversity Conserva>on and Management (Oxford University); First class BA Hons Classics (UCL)
23
Spinout from the department of Biochemical Engineering
Team have been close friends for eight years
What will OneStart mean to us?
24
We plan to develop, test at scale and then license our technology £100k – matched with TSB SMART, will allow us to….
• Design and build an industrial scale prototype • Test prototype at UCL using industrial facilities • Base a demo/development rig at the Stevenage BioScience Catalyst • Cover costs for first feasibility study with end user
OneStart advice and support will help us to execute our plan
• Network memberships will provide end user and licensee access • Lab space can be used for prototype refinement and demonstrations • Legal advice vital for licence model
OneStart would take Puridify to an investment inflection point • Product proved in-house at relevant industrial scale • Data will add value for future licensee negotiations
Pym
An integrated platform for mobile diagnostics, bringing a laboratory to the phone in your hand
Pym
James Flewellen Irwin Zaid Postdoctoral Researcher at University of Oxford
Junior Research Fellow at Christ Church, University of Oxford
Pym and OneStart
£100k to: • Develop a prototype device • Optimise urinalysis software • Rent cloud servers for processing and storage • Design a mobile app
Superior Low Toxic Nano-‐delivery Technology for Stem Cell Therapy
STEM
Team Name: TECREA-‐STEM
Dr. Nidhin Raj Sales and Marketing Manager
Dr. Kantaraja Chindera, Business Development Director
Dr. Mittal Shah, Stem Cell Research Study Director
Mrs Klaudia Muniak, Laboratory Manager
Miss Fadhilah Kamaruzzaman, R&D Scientist I
Dr. Bhagyalakshmi Chengat Prakashbabu, R&D Scientist II
Tecrea-Stem Team
How the 100 K will help you advance your idea
We already have in-‐house and external lab based evidence demonstra0ng that our technology works for biomolecules delivery into eukaryo0c and prokaryo0c cells. We envision that with further op0misa0on in the formula0ons, our technology has an immense poten0al to overcome the important problem of biomolecule delivery in the stem cell sector, which will enable improved research and transla0on into the clinic. • OneStart funding will help us to op0mise condi0ons for improved delivery of DNA, RNA and protein into hard to transfect primary and stem cells. This would help to improve stem cell reprogramming efficiency and advance stem cell research and therapy.
• The outcome will be superior, non-‐toxic delivery technology specifically formulated for primary and stem cell applica0ons. This will strategically posi0on Tecrea-‐stem within the stem cell sector and allow us to capture a substan0al por0on of a rapidly growing, high margin market.
• Revenue generated from product sale would help us to fund other applica0ons of our technology, including in-‐house therapeu0c stem cell reprogramming R&D.
• Success with Tecrea-‐stem will enable us to raise further funding for other applica0ons of this technology in clinics (eg for an0microbial delivery).